Tag Archives: setback

Promising new drug for aggressive stage IV breast cancer encounters setback

Federal approval of a highly anticipated breast cancer drug was delayed by the Food and Drug Administration this week. The drug, sacituzumab govitecan, which is produced by Immunomedics, was previously designated a “breakthrough therapy” by the FDA “based on preliminary evidence that it demonstrates substantial improvement over existing therapies for a life threatening disease.” According… Read More »